DSM ComfortCoat® Hydrophilic Coating Utilized in New Drug Eluting Stent Delivery System from CID SpA
BERKELEY, Calif.--(BUSINESS WIRE)--DSM, a global leader in biomedical materials science, today announced the use of its ComfortCoat® hydrophilic coating on the delivery system of CID SpAs new Cre8™ Drug Eluting Stent (DES), CE marked the 16th of July 2011.
"As DSMs materials portfolio continues to expand with novel coating materials, the successful launch of Cre8 DES is another strong testament to the value we provide medical device manufacturers across the globe."
CID SpA chose ComfortCoat® hydrophilic coating, a proprietary DSM product and technology, since it facilitates the treatment of more complex patient anatomies by enhancing the deliverability of its stentdelivery systems during percutaneous coronary intervention procedures.
Recently released data has not only proven the unmatched effectiveness of Cre8™ DES in patients with coronary artery disease, but showcases the potential for this type of drug eluting stent system to help physicians shorten the dual antiplatelet therapy period for their patients.Further, CID is leveraging the latest advanced delivery system technologies, particularly the ComfortCoat® hydrophilic coating, in order to maximize acute device performances.
"The launch of Cre8 DES aligns with our mission of supporting interventional cardiologists and their patients with the development of innovative systems that positively impact patient outcomes, in terms of efficacy and safety, while also helping to reduce costs within the healthcare delivery system," said Franco Vallana, president and CEO of CID SpA. "By collaborating with DSM, we are able to ensure interventional cardiologists receive the benefits of the worlds most advanced technologies within our drug eluting stent systems."
"Our long-standing partnership with CID reaffirms our continued commitment to providing innovative material solutions for the cardiovascular market, which, ultimately, help to lower patient risk and improve procedural outcomes," said John Marugg, Business Manager Coatings, DSM Biomedical. "As DSMs materials portfolio continues to expand with novel coating materials, the successful launch of Cre8 DES is another strong testament to the value we provide medical device manufacturers across the globe."
This announcement precedes the start of COMPAMED, where DSM will be exhibiting in Hall 8a at booth K28 from November 16-18, 2011 in DÃ¼sseldorf, Germany.
DSM – Bright Science. Brighter Living.™
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements,personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSMs 22,000 employees deliver annual net sales of about â‚¬ 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
CID (Carbostent & Implantable Devices) is dedicated to contributing to human welfare by improving the quality of patient care and after-care through the development of innovative, minimally invasive implantable devices, procedures and therapies. A strong background in the field of implantable cardiovascular devices and haemocompatible materials, expressed in a remarkable IP portfolio, and a management with an expertise gained in many years of research, development and clinical experience, allow CID to offer the investors a fair return and its customers the necessary tools to meet new challenges.
ComfortCoat® is a registered trademark of Royal DSM N.V.
Cre8™ is a trademark of CID SpA.